Stocks and Investing
Stocks and Investing
Wed, November 15, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, November 14, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Louise Chen Downgraded (ACRS) to Hold on, Nov 14th, 2023
Louise Chen of Cantor Fitzgerald, Downgraded "Aclaris Therapeutics, Inc." (ACRS) to Hold on, Nov 14th, 2023.
Louise has made no other calls on ACRS in the last 4 months.
There are 3 other peers that have a rating on ACRS. Out of the 3 peers that are also analyzing ACRS, 2 agree with Louise's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Alex Thompson of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $2 on, Monday, November 13th, 2023
- Tim Lugo of "William Blair" Downgraded from Buy to Hold on, Monday, November 13th, 2023
This is the rating of the analyst that currently disagrees with Louise
- Gavin Clark-Gartner of "Evercore ISI Group" Initiated at Buy and Held Target at $22 on, Tuesday, October 3rd, 2023
Contributing Sources